Beijing: Chinese biotechnology company Clover Biopharmaceuticals said that a large trial shows its two-dose Covid-19 vaccine is 79% effective against the fast-spreading Delta variant.
The vaccine candidate is 92% effective against the Gamma variant first identified in Brazil, and 59% against the Mu variant first detected in Colombia, according to joint statement issued by the company and the Coalition for Epidemic Preparedness Innovations, a nonprofit organisation that funded the clinical trial.
The vaccine’s overall efficacy rate against all strains in the study was 67%. It was also 100% effective in preventing severe cases and hospitalisations, and nearly 84% effective in preventing moderate to severe cases, the statement said.
The vaccine is the “first Covid-19 vaccine to demonstrate significantly reduced risk of Covid-19 disease in previously infected individuals, a growing and increasingly important population as SARS-CoV-2(the novel coronavirus that causes the disease) continues to spread globally”, it said.
The protein-based vaccine uses protein fragments of the virus to trigger immune responses, and requires the use of an adjuvant to achieve desired protection.
Clover Biopharmaceuticals, which is based in Chengdu, Sichuan province, said its adjuvant is supplied by the US company Dynavax.
More than 30,000 adults – some of them elderly – in the Philippines, Brazil, Colombia, South Africa and Belgium were enrolled in mid- and late-stage clinical trials. They were either given two doses administered 21 days apart or a placebo. — China Daily/ANN